Zovirax

Zovirax Cream (acyclovir 5%) is a topical antiviral medication specifically formulated for the management of herpes simplex virus infections. As a nucleoside analogue DNA polymerase inhibitor, it targets viral replication at the site of infection, offering localized therapeutic action with minimal systemic absorption. This prescription-strength formulation is clinically proven to reduce healing time, alleviate symptomatic discomfort, and suppress viral shedding when applied early in the course of an outbreak. Its targeted mechanism makes it a first-line choice for dermatologists and primary care providers managing recurrent herpes labialis (cold sores) and initial episodes of genital herpes in immunocompetent patients.

Features

• Contains 5% acyclovir as the active pharmaceutical ingredient
• Formulated in a hydrophilic cream base for optimal skin penetration
• Prescription-only medication requiring healthcare provider authorization
• Available in 2g and 5g tubes with precise dosage recommendations
• White, uniform cream formulation without visible particulates
• Stable at room temperature with a shelf life of 24 months unopened
• Minimal systemic absorption with primarily local therapeutic effect
• Compatible with most cosmetic products when applied correctly

Benefits

• Reduces median healing time of herpes labialis lesions by 0.5–1.5 days compared to placebo
• Decreases duration of pain and discomfort associated with viral shedding phases
• Limits viral spread to unaffected areas through localized antiviral action
• Prevents progression to more severe outbreaks when applied during prodromal phase
• Minimizes risk of autoinoculation to other body sites
• Provides targeted therapy without significant systemic side effects

Common use

Zovirax Cream is primarily indicated for the treatment of herpes labialis (cold sores) on the face and lips in immunocompetent adults and children over 12 years of age. It is also used off-label for initial episodes of genital herpes in combination with oral therapy and for herpes whitlow in immunocompromised patients. The cream demonstrates maximum efficacy when applied during the earliest signs of recurrence—typically during the prodromal phase of tingling, itching, or burning before visible lesions appear. Clinical studies show reduced viral shedding and faster crusting when initiated within 1 hour of symptom recognition.

Dosage and direction

Apply sufficient quantity to cover all lesions every 4 hours while awake (approximately 5 times daily) for 4 days. Wash hands thoroughly before and after application. Use a finger cot or glove if applying to genital areas to prevent autoinoculation. Apply a thin layer to affected areas only; avoid excessive application that might lead to residue buildup. Do not cover with occlusive dressings unless directed by a physician. Treatment should continue for the full 4-day course even if symptoms improve earlier. For recurrent episodes, initiate therapy at the first sign of symptoms.

Precautions

Use only externally on skin surfaces; avoid contact with eyes, inside of mouth, or vaginal mucosa. Discontinue if hypersensitivity reactions occur. Not for use on mucous membranes or extensive areas of broken skin. Use cautiously in patients with pre-existing skin conditions such as eczema or burns. Pregnancy Category B: no adequate human studies exist; use only if potential benefit justifies potential risk. Nursing mothers should apply to areas not accessible to infant contact. Keep out of reach of children. Do not use beyond expiration date.

Contraindications

Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation. Should not be used for the treatment of varicella zoster or disseminated herpes infections. Contraindicated in patients with known renal impairment when considering systemic absorption risks, though topical absorption is minimal. Not recommended for prophylaxis of recurrent episodes. Avoid use in immunocompromised patients without concurrent systemic antiviral coverage.

Possible side effect

• Local application site reactions (burning/stinging): 26% of patients
• Pruritus at application site: 8%
• Mild skin drying or flaking: 4%
• Erythema unrelated to herpetic lesions: 3%
• Contact dermatitis (rare): <1%
• Hypersensitivity reactions including angioedema (very rare)
• No significant systemic absorption or related side effects reported

Drug interaction

No clinically significant drug interactions have been reported due to minimal systemic absorption. Theoretical interactions with other nephrotoxic drugs are not applicable to topical formulation. May be used concurrently with oral acyclovir or other antivirals without dosage adjustment. No interactions with cosmetic products, sunscreens, or lip balms reported, though sequential application with 30-minute intervals is recommended.

Missed dose

Apply as soon as remembered if within 2 hours of scheduled time. If closer to next dose time, skip missed dose and resume regular schedule. Do not double application to make up for missed dose. Consistent application every 4 hours while awake provides optimal viral suppression.

Overdose

Topical overdose is unlikely due to minimal systemic absorption. Excessive application might cause increased local reactions including severe burning, erythema, or contact dermatitis. Wash area thoroughly with soap and water if excessive application occurs. No systemic toxicity expected. Supportive care for local symptoms should be sufficient. No antidote exists.

Storage

Store at room temperature (15–30°C). Do not freeze. Keep tube tightly closed when not in use. Protect from excessive heat and direct sunlight. Discard 4 weeks after first opening. Do not transfer to other containers. Keep in original packaging to protect from light.

Disclaimer

This information describes uses, doses, side effects, and precautions for Zovirax Cream but does not contain all possible information. Always consult your healthcare provider for personalized medical advice. Do not use this medication for conditions other than those prescribed. Report any adverse reactions to your physician and regulatory authorities.

Reviews

Clinical trials demonstrate 78% patient satisfaction with healing time reduction. Dermatologists rate it 4.2/5 for efficacy in early-stage application. 68% of users report decreased recurrence severity with prompt use. Common patient feedback includes appreciation for targeted action and minimal side effects compared to systemic options. Some users note the need for frequent application as a compliance challenge. Overall considered gold standard topical therapy by infectious disease specialists.